RX-5902, an inhibitor that binds directly to phosphorylated DDX5, a post-translational modification of DDX5 which mediates epithelial to mesenchymal transition only in transformed cancer cells, is being studied in Phase I clinical trials for treatment of triple negative breast cancer [86]. The gene discussed is DDX5; the disease is triple-negative breast carcinoma.